Lung cancer drug lorbrena under Post-Market safety review
NCT ID NCT03844464
First seen Nov 01, 2025 · Last updated Jun 12, 2026 · Updated 32 times
Summary
This study looked at side effects of the drug Lorbrena in 1290 people with non-small cell lung cancer after it was already on the market. The main focus was on nervous system problems and liver issues. The goal was to better understand what factors might increase these risks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
3-22-7, Yoyogi, Shibuya-ku
Tokyo, 151-8589, Japan
Conditions
Explore the condition pages connected to this study.